Sodium-glucose transporter-2 inhibition as an antidiabetic therapy
نویسندگان
چکیده
منابع مشابه
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce the complications associated with type 2 diabetes mellitus...
متن کاملSafety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملSodium glucose transporter‐2 inhibition has no renoprotective effects on non‐diabetic chronic kidney disease
Sodium glucose transporter (SGLT)-2 inhibition has renoprotective effects in diabetic kidney disease. Whether similar effects can be achieved also in non-diabetic kidney disease is speculative. Chronic kidney disease was induced in C57BL/6N mice by feeding an oxalate-rich diet for 14 days, known to induce nephrocalcinosis-related tubular atrophy and interstitial fibrosis without directly affect...
متن کاملSodium-Glucose Transporter Type 2 (SGLT2) Inhibitor for Diabetic Kidney
In diabetes, both activation of renin-angiotensin system and glomerular hyperfiltration are seen even before the development of diabetic nephropathy. Glomerular hyperfiltration depends on glomerular hypertension sue to pathophysiological afferent arteriolar dilation. Tubular hypothesis has been proposed more than a decade ago to explain the above in type1 diabetes. Recently, clinical evidences ...
متن کاملSodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced. Unlike many current therapies, the mechanism of action of SGLT2 inhibitors is independent of insulin action or beta-cell function. In addition, the mechanism of action of SGLT2 inhibitors is co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2010
ISSN: 0931-0509,1460-2385
DOI: 10.1093/ndt/gfq249